Harrow Inc. (NASDAQ:HROW) shares are down during Tuesday’s premarket session as the company faces scrutiny following its recent financial results announcement.
The eye disease medicine maker, Harrow, reported fourth quarter earnings of 17 cents per share, missing the consensus estimate of 38 cents.
Sales jumped from $66.81 million to $89.09 million, beating the consensus of $88.45 million.
During the fourth quarter and full-year ended December 31, 2025, Harrow recorded $8.5 million in acquired in-process research and development expenses related to its acquisition of Melt Pharmaceuticals.
Management Commentary
“I also believe we are going to provide positive surprises this year (and next) with a few products in our portfolio that haven’t received much attention. With multiple growth drivers gaining traction and a larger commercial footprint coming online, I have increasing confidence in our ability to accelerate performance through 2026, to remain on track toward our goal of over $250 million in quarterly revenue by the end of 2027,” said Mark Baum, CEO of Harrow.
“And that won’t be the end of the story because beginning in 2028, we intend to further leverage our commercial platform by launching late-stage, large market assets in development, like G-MELT (formerly MELT-300), YOCHIL (formerly MELT-210), a next-generation TRIESENCE pre-filled syringe, and other high-impact product candidates in other phases of review,” Baum further commented on Monday.
Baum expressed confidence in the company’s ability to deliver positive surprises with several products in development, emphasizing a commitment to transparency in financial guidance moving forward.
Harrow expects fiscal 2026 sales of $350 million-$365 million, below the consensus estimate of $386.26 million.
Technical Analysis
The stock is currently trading 14.76% below its 20-day simple moving average (SMA) and 12.34% below its 100-day SMA, indicating a bearish trend. Over the past 12 months, shares have decreased significantly, and they are currently positioned closer to their 52-week lows than highs.
The RSI is at 44.45, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.15, below its signal line at 0.22, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential volatility in the near term.
- Key Resistance: $54.50
- Key Support: $20.85
HROW Price Action: Harrow shares were down 12.32% at $46.99 during premarket trading on Tuesday, according to Benzinga Pro data.
Image by Rulo Jmp via Shutterstock
